ストックスクリーナーアプリを入手
3.005
1.64%
-0.045
前日終値:
$3.05
開ける：
$3.05
24時間の取引高:
206.51K
Relative Volume:
0.41
時価総額：
$2.27M
収益：
$202.00K
当期純損益:
$-28.96M
株価収益率:
-5.0083
EPS:
-0.6
ネットキャッシュフロー:
$-21.85M
1週間 パフォーマンス:
-64.35%
1か月 パフォーマンス:
-65.32%
6か月 パフォーマンス:
+1,386%
1年 パフォーマンス:
+733.56%
1日の値動き範囲:
$2.92
$3.1837
1週間の範囲:
$2.92
$20.35
52週間の値動き範囲:
$0.0633
$20.35
AIM ImmunoTech Inc Stock (AIM) Company Profile
AIM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
2.97 | 2.41M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.03 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
544.62 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
389.21 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.00 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
300.65 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc (AIM) 最新ニュース
AIM ImmunoTech's $8.0M Capital Raise: A Strategic Move to Fuel Ampligen's Clinical Progress and Investor Value? - AInvest
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering - GlobeNewswire
AIM ImmunoTech Secures $8M Funding: New Shares at $4.00 Plus 5-Year Warrants - Stock Titan
Biotech Alert: Searches spiking for these stocks today - TipRanks
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - GlobeNewswire
Evaluating AIM ImmunoTech's Capital Raise: A Strategic Crossroads for Investors - AInvest
AIM Shares Fall After Pricing of $8 Million Public Offering - MarketScreener
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga
AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com Australia
AIM ImmunoTech stock plunges after pricing $8 million public offering By Investing.com - Investing.com India
US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings - Benzinga
AIM ImmunoTech prices $8 million public offering at $4.00 per share - Investing.com
AIM ImmunoTech Plunges 51.11% Amid Market Volatility - AInvest
AIM ImmunoTech prices 2M shares at $4.00 in public offering - TipRanks
AIM ImmunoTech Secures Fresh Capital: $8M Offering Includes Dual Warrant Structure at $4.00 - Stock Titan
AIM ImmunoTech Inc Plunges 38.33% Amid Trading Halt - AInvest
AIM ImmunoTech Stock Plunges 40.97% on Volatility - AInvest
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
AIM ImmunoTech Reports Positive Mid-year Safety and - GlobeNewswire
AIM ImmunoTech Inc. Trading Resumes: Enhanced Tools and Expert Analysis Available for Investors - AInvest
Crude Oil Gains 2%; CEA Industries Shares Spike Higher - Benzinga
Why Is Micro-Cap AIM ImmunoTech Stock Surging? - Benzinga
AIM ImmunoTech's Ampligen: A Promising Catalyst for Shareholder Value in Pancreatic Cancer Therapy - AInvest
US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings - Benzinga
AIM ImmunoTech Reports Positive Phase 2 Study Results - TipRanks
AIM ImmunoTech (AIM) reveals positive Phase 2 Ampligen pancreatic data | AIM SEC FilingForm 8-K - Stock Titan
Breakthrough in Pancreatic Cancer Treatment: New Phase 2 Data Shows 64% Survival Rate at 6 Months - Stock Titan
AIM ImmunoTech (NYSE:AIM) Stock Price Down 4.5% – Here’s What Happened - Defense World
Latest News - Asia Food Journal
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
Omega Therapeutics (NASDAQ:OMGA) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Review - Defense World
AIM ImmunoTech Reveals Major European Expansion Plan for Cancer Drug Development - Stock Titan
AIM ImmunoTech (NYSE:AIM) Shares Gap Up – Here’s What Happened - Defense World
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements - The Manila Times
AIM ImmunoTech's Compliance Clock Ticks: Can Equity Challenges Be Overcome Before June 2026? - AInvest
AIM ImmunoTech resumes trading on NYSE American By Investing.com - Investing.com India
AIM ImmunoTech resumes trading on NYSE American - Investing.com
AIM ImmunoTech Resumes Trading on NYSE American - The Manila Times
AIM ImmunoTech Inc. Common Stock Resumes Trading on NYSE American - Nasdaq
Aim Immunotech CEO Thomas Equels acquires $823 in common stock By Investing.com - Investing.com India
Aim Immunotech CEO Thomas Equels acquires $823 in common stock - Investing.com
Aim Immunotech CEO Thomas Equels acquires shares worth $896 By Investing.com - Investing.com Nigeria
Aim Immunotech CEO Thomas Equels acquires shares worth $896 - Investing.com Australia
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension - GlobeNewswire
AIM ImmunoTech Regains NYSE Compliance, Stock Reinstated - TipRanks
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen® - The Manila Times
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, ... - Bluefield Daily Telegraph
New Patent Grant Extends Ampligen Manufacturing Protection for 18 Years: Major Win for Cancer and COVID Drug - Stock Titan
NYSE American Lifts AIM ImmunoTech Trading Ban After Stock Price Recovery - Stock Titan
AIM ImmunoTech's Reverse Stock Split: A Strategic Move to Avoid Delisting or a Risky Gamble? - AInvest
AIM ImmunoTech Inc (AIM) 財務データ
収益
当期純利益
現金流量
EPS
3.57%
1.64%
大文字化:
|
ボリューム (24 時間):